2 diabetes, alzheimer, blood glucose level, blood pressure, blood sugar, blood sugar control, blood sugar levels, bmi, body mass index, cardiovascular, cardiovascular disease, cardiovascular fitness, causes diabetes, children, cholesterol, complications of diabetes, dairy, dash diet, depression, diabetes, diabetes care, diabetes mellitus, diabetes research, diabetes treatment, diabetes type, diet, digestive, energy drinks, exercise, exercise routines, fitness, food, food groups, gestational diabetes, glucose, hdl, health, healthy blood sugar, healthy diet, healthy fats, healthy food, healthy weight, hearing, hearing impairment, heart disease, high blood sugar, high calorie diet, history of diabetes, hormone, hypertension, immune system, insulin, ketones, Lose Weight, medical problems, mediterranean diet, metabolism, mobility, muscle, muscle strengthening activities, nutrient dense foods, nutrition, nuts, obesity, Pancreas, people with diabetes, physical activity, plant based diet, portion control, portion sizes, prehypertension, processed foods, protein, refined carbohydrates, skin, smoking, strength, stress, stress eating, stroke, sugar, sugar levels, the mediterranean diet, trans fat, Triglycerides, type 1 diabetes, type 2 diabetes, types of diabetes, ulcers, vegan diet, vegetables, what causes diabetes, whole grains.
Around 75% of people with diabetes have type 2 diabetes mellitus. This was earlier termed non-insulin dependent diabetes mellitus (NIDDM) or maturity-onset diabetes mellitus. The number of people with type 2 diabetes is rapidly increasing. In type 2 diabetes, not enough insulin is produced or the insulin that is made by the body is insufficient to meet the needs of the body. Obesity or being overweight predisposes to type 2 diabetes.
The prognosis of diabetes is related to the extent to which the condition is kept under control to prevent the development of the complications described in the preceding sections. Some of the more serious complications of diabetes such as kidney failure and cardiovascular disease, can be life-threatening. Acute complications such as diabetic ketoacidosis can also be life-threatening. As mentioned above, aggressive control of blood sugar levels can prevent or delay the onset of complications, and many people with diabetes lead long and full lives.
Complaints about preventative go back to the late 18th century. The spelling reformer James Elphinston wrote in 1787 that preventative could be heard among Londoners in unguarded speech, along with other disapproved pronunciations like umberella and mischievious that sneak in an extra syllable (a process that linguists call "epenthesis"). A 1795 review of the Earl of Lauderdale's "Letters to the Peers of Scotland" criticized the appearance of preventative in the text, declaring that it was "not English." Similarly, Francis Barnett took Andrew Reed's "No Fiction" to task in 1823 for including the word: "In the English language there is no such word as preventative, preventive there is."
Big pharma are in the early stages of developing their own cell therapy approaches for diabetes. Novo Nordisk, one of the largest providers of diabetes treatments, is bidding for stem cells and an encapsulation device, stating that the first clinical trial could take place in the “next few years.” Sanofi, also a big name in diabetes, is working with the German Evotec in a beta cell replacement therapy for diabetics.
Type 2 DM begins with insulin resistance, a condition in which cells fail to respond to insulin properly. As the disease progresses, a lack of insulin may also develop. This form was previously referred to as "non insulin-dependent diabetes mellitus" (NIDDM) or "adult-onset diabetes". The most common cause is a combination of excessive body weight and insufficient exercise.
Benari doesn’t want to remain an outlier, though. And perhaps surprisingly, many doctors and surgeons are starting to agree that surgery should be considered more than a last-resort remedy for weight loss. Instead, it should be seen as a crucial aspect of diabetes care, and quite possibly the best tool we have against the chronic, often worsening condition.
The WHO estimates that diabetes mellitus resulted in 1.5 million deaths in 2012, making it the 8th leading cause of death. However another 2.2 million deaths worldwide were attributable to high blood glucose and the increased risks of cardiovascular disease and other associated complications (e.g. kidney failure), which often lead to premature death and are often listed as the underlying cause on death certificates rather than diabetes. For example, in 2014, the International Diabetes Federation (IDF) estimated that diabetes resulted in 4.9 million deaths worldwide, using modeling to estimate the total number of deaths that could be directly or indirectly attributed to diabetes.
As a global network of medical research charities, the Juvenile Diabetes Research Foundation (JDRF) is driving research into new treatments that present tremendous opportunities to deliver enhanced health and wellbeing for people with type-1 diabetes. The technology I am currently most enthused about is glucose responsive insulin, which I think is going to transform how people treat and live with type 1 in the future.
In diabetes, either the pancreas makes insufficient levels of insulin so cells absorb glucose poorly or cells themselves become insulin resistant and thus unable to absorb glucose despite adequate insulin levels. Both types of change increase blood sugar levels above normal. Parsed this way, type I and type II diabetes overlap some but also differ.
Innovation in technology is not just fuelling advances in diabetes treatments though. I know it will accelerate the path to the cure. And this is what unites people with type-1 diabetes, researchers, our charitable supporters and funders. I am convinced one day we will consign type 1 to the history books and no one will ever receive this life-changing diagnosis again.
Also known as smart insulin, Professor John Fossey at the University of Birmingham is developing this type of insulin delivery system which is designed to circulate in the body, inactive, until blood glucose levels start to rise. As they do, the insulin goes to work to bring these levels back down, ensuring perfect glucose control throughout any given day.
Oskar Minkowski and Joseph Von Mering met accidently in a library in 1889. Striking up a conversation, they began to debate whether the pancreas helped digest and absorb fats. Performing a pancreatectomy on a dog that same night, they found the dog developed glycosuria, a condition associated with diabetes that causes the production of a lot of urine. Minkowski found the urine was 12% sugar. They then depancreatized another dog and found that prevented hyperglycemia.
One of the most advanced alternatives comes from the Diabetes Research Institute (DRI) in the US, which is developing a bioengineered mini-organ where insulin-producing cells are encapsulated within a protective barrier. Two years ago, the DRI announced that the first patient treated in an ongoing Phase I/II trial no longer requires insulin therapy.
When Jair Bolsonaro won Brazil’s presidential election in October to the consternation of the country’s traditional political elite, commentators were sharply divided about the implications. Some warned that Bolsonaro, a far-right populist who has openly expressed admiration for the brutal military dictatorship that ruled Brazil from 1964 to 1985, presented a clear and present threat to democracy. Others argued that Brazil’s strong institutions, including its aggressive press and fiercely independent judiciary, would rein in his authoritarian tendencies.
“I am extremely pleased to see that technology developed in Tejal Desai’s group is getting to the point that we can explore this for therapeutic purposes,” Matthias Hebrok, PhD, the director of the Diabetes Center at UCSF and a member of Encellin’s scientific advisory board, noted on the UCSF website. “Encapsulation and protection of islet cells remain a critical hurdle that needs to be overcome before cell therapy becomes a reality in type 1 diabetes.”
Diarrhea and constipation may also stem from diabetes-related gut movement issues. And the conditions may be related. “Diarrhea doesn’t mean fast motion; constipation doesn’t mean slow movement,” says Mashimo, happy to clear up a common misconception. “They can be two sides of the same coin.” Constipation, he says, is caused by slow movement of the bowels, which can cause a buildup of harmful bacteria in the colon that, in turn, triggers diarrhea.
People with full-blown type 2 diabetes are not able to use the hormone insulin properly, and have what’s called insulin resistance. Insulin is necessary for glucose, or sugar, to get from your blood into your cells to be used for energy. When there is not enough insulin — or when the hormone doesn’t function as it should — glucose accumulates in the blood instead of being used by the cells. This sugar accumulation may lead to the aforementioned complications.